Diligence memo · auto-generated · as of July 3, 2026
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Arsenal Biosciences, Inc. operates in Biotechnology, based in South San Francisco.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Arsenal Biosciences, Inc. has raised $579M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $325M on 2024-07-09.
Most recent recorded round closed around 2024-07-09.
Valuation (modeled)modeled
Provath models Arsenal Biosciences, Inc. at approximately $3.5B (range $1.5B–$4.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.76× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 24 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.